

## HOLD TP: Rs 340 | A 11%

LAURUS LABS

Pharmaceuticals

28 April 2023

## **Dismal quarter**

- Q4 a miss on all fronts revenue/EBITDA/PAT below consensus by 16%/35%/55%
- EBITDA margin at a 3Y low of 21% owing to a change in mix and high costs; PAT down 49% QoQ
- We cut FY24 PAT by 35% and roll over to a new TP of Rs 340 (vs. Rs 540) based on 12x EV/EBITDA (vs. 14x); maintain HOLD

**Miss on revenue owing to below-expected CDMO:** Laurus posted one of its weakest quarterly prints in Q4FY23 with subpar revenue in CDMO/FDF, further exacerbated by a shift towards low-margin business. Revenue/EBITDA/PAT declined 11%/29%/49% QoQ and missed consensus estimates by 16%/35%/55%.

**Shift in business mix causes lowest margin in three years:** Gross margin contracted 375bps QoQ to 49.7% (-235bps YoY) due to a change in business mix as well as a significant price decline in the ARV portfolio (APIs as well as formulations). Negative operating leverage arising out of lower revenue and commissioning of new capacities took a further toll, resulting in EBITDA margin contraction of 545bps QoQ to 20.7% (-715bps YoY).

**FY24 to be a year of consolidation:** Laurus did not record any sales from the Global Fund order during the quarter, but this order will help the company use its capacities over the next three years, reliving some stress from the negative operating leverage seen in Q4. Management believes that excess channel inventory and adverse pricing are near the bottom and that FY24 is going to be a year of consolidation.

**Retain HOLD:** We believe Laurus has long-term growth levers in place to improve its margin trajectory and profitability via increased utilisation of new capacities, supplies to Global Fund from FY24, and 60 active projects in the CDMO. However, the near-term outlook remains challenging given the lack of large CDMO contracts, excess channel inventory and continued pricing challenges, resulting in margin pressure from negative operating leverage. We cut FY24 earnings estimates by ~35% and roll forward to a revised TP of Rs 340 (vs. Rs 540), based on 12x FY25E EV/EBITDA (earlier 14x). Maintain HOLD.

# Kayahangaa

Saad Shaikh

research@bobcaps.in

Target	Rating
<b>•</b>	<►
Ticker/Price	LAURUS IN/Rs 308
Market cap	US\$ 2.0bn
Free float	74%
3M ADV	US\$ 8.4mn
52wk high/low	Rs 606/Rs 279
Promoter/FPI/DII	27%/23%/5%

Source: NSE | Price as of 28 Apr 2023

### Key financials

FY23P	FY24E	FY25E
60,410	62,744	69,525
15,926	14,117	17,034
7,906	6,516	8,423
14.7	12.1	15.7
14.7	16.5	20.1
21.4	15.1	17.0
20.9	25.3	19.6
11.5	13.2	10.9
(4.6)	(17.6)	29.3
	60,410 15,926 7,906 14.7 14.7 21.4 20.9 11.5	60.410         62,744           15,926         14,117           7,906         6,516           14.7         12.1           14.7         16.5           21.4         15.1           20.9         25.3           11.5         13.2

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

### Stock performance



Source: NSE



### Fig 1 – Quarterly performance

(Rs mn)	Q4FY23	Q4FY22	YoY (%)	Q3FY23	QoQ (%)	FY23	FY22	YoY (%)
Net Sales	13,809	14,248	(3.1)	15,448	(10.6)	60,406	49,356	22.4
EBITDA	2,855	3,967	(28.0)	4,036	(29.2)	15,922	14,224	11.9
Depreciation	870	657	32.4	844	-	3,241	2,515	-
EBIT	1,985	3,310	-	3,191	-	12,681	11,709	-
Interest	531	306	-	427	-	1,652	1,024	-
Other Income	17	13	-	14	-	60	153	-
PBT	1,471	3,017	(51.2)	2,779	(47.0)	11,089	10,839	2.3
Less: Taxation	399	698	(42.8)	748	-	3,123	2,514	-
Less: Minority Interest	42	14	-	0	-	65	49	-
Recurring PAT	1,030	2,305	(55.3)	2,030	(49.3)	7,902	8,275	(4.5)
Exceptional items	0	0	-	0	-	0	0	-
Reported PAT	1,030	2,305	(55.3)	2,030	(49.3)	7,902	8,275	(4.5)
Key Ratios (%)			(bps)		(bps)			(bps)
Gross Margin	49.7	52.0	(235)	53.4	(373)	54.1	55.6	(148)
EBITDA Margin	20.7	27.8	(716)	26.1	(545)	26.4	28.8	(246)
Tax / PBT	27.1	23.1	-	26.9	-	28.2	23.2	-
NPM	7.5	16.2	(872)	13.1	(568)	13.1	16.8	(369)
EPS (Rs)	1.9	4.3	(55.4)	3.8	(49.3)	14.7	15.5	-

------

### Fig 2 – Revenue mix

(Rs mn)	Q4FY23	Q4FY22	YoY (%)	Q3FY23	QoQ (%)	FY23	FY22	YoY (%)
Generics – API	7,140	5,390	32.5	6,320	13.0	26,090	20,390	28.0
ARVs	3,499	2,965	18.0	3,729	(6.2)	15,090	12,490	20.8
Oncology	1,285	701	83.4	758	69.5	3,195	2,890	10.5
Other API	2,356	1,725	36.6	1,833	28.6	7,805	5,010	55.8
Synthesis	2,280	3,600	(36.7)	6,420	(64.5)	21,670	9,170	136.3
Formulations	3,930	4,910	(20.0)	2,490	57.8	11,400	18,800	(39.4)
Bio	460	350	31.4	220	109.1	1,250	1,000	25.0
Net Sales	13,809	14,248	(3.1)	15,449	(10.6)	60,406	49,356	22.4

Source: Company, BOBCAPS Research



### Fig 3 – Revenue



Source: Company, BOBCAPS Research

### Fig 5 – EBITDA margin






Fig 4 – EBITDA







Source: Company, BOBCAPS Research

## Earnings call highlights

- Business highlights: Laurus's Q4FY23 revenue declined 3% YoY due to lower sales in CDMO-Synthesis and ARV FDF. Though there was sequential recovery in ARV FDF volumes, pricing remained depressed. API business saw a healthy uptick, both YoY and QoQ.
  - Formulations (FDF): FDF saw a sequential recovery of 58%, but a 20% decline YoY due to soft ARV demand and weak pricing. Developed market growth was stable with higher generic volumes.
  - APIs: All API segments did well and the business reported strong 33% YoY growth. Steady ramp-up continued in the other API business (+37%) along with ARV (+18%) and oncology APIs (+83%).
  - Synthesis: The synthesis business declined of 65% QoQ and 37% YoY due to completion of supplies related to a large purchase order in Dec'22. Per the company, Q4 baseline business is seeing healthy momentum and the project pipeline continues to scale up. Expansion in integrated CDMO capabilities (including R&D centre and Animal Health) is on track.



- Bio: The business delivered strong recovery with +31% YoY growth (+109% QoQ) in Q4.
- Guidance
  - Revenue: Laurus expects FY24 to be a year of consolidation and has guided for flat-to-moderate topline growth given a high base of FY23 which had large contract wins.
  - Margins: Management expects the EBITDA margin to improve from Q1FY24 onwards aided by operating leverage.
  - **Capex:** Laurus spent Rs 9.5bn in capex during FY23 with Rs 10.5bn to be invested in FY24.
- Margins: The Q4 gross margin at 49.7% decreased by 235bps YoY and 375bps QoQ due to a change in product mix and pricing pressure in the ARV portfolio.
   EBITDA margin at 20.7% decreased by 715bps YoY and 545bps QoQ.
- **FDF capacity:** Current utilisation of the Rs 10bn-unit FDF capacity is at ~55% which management expects will improve to ~70% by end-FY24.
- Global Fund supplies: Shipments have begun but were not meaningful in Q4. Being a panel supplier, the company is assured of making supplies over the next three years.
- R&D: R&D spend for FY23 stood at Rs 2.1bn or 3.5% of sales, with similar levels guided for FY24. The new R&D centre (FY24) and commercial GMP manufacturing for an animal health contract will be initiated from H2FY24.
- **Tax rate:** With a move to the new tax regime, the effective tax rate is guided at 25% from FY24 onwards.



## Valuation methodology

We believe Laurus has long-term growth levers in place to improve its margin trajectory and profitability via increased utilisation of new capacities, supplies to Global Fund from FY24, and 60 active projects in the CDMO. However, the near-term outlook remains challenging given the lack of large CDMO contracts, excess channel inventory and continued pricing challenges, resulting in margin pressure from negative operating leverage. We cut our FY24 earnings estimates by ~35% and roll valuations forward to FY25E for a revised TP of Rs 340 (vs. Rs 540), based on 12x EV/EBITDA (vs. 14x). Maintain HOLD.

### Fig 7 – Revised estimates

(Rs bn)	Nev	New		k	Change (%)	
	FY24E	FY25E	FY24E	FY25E	FY24E	FY25E
Sales	62.7	69.5	65.1	NA	(3.7)	-
EBITDA	14.1	17.0	18.9	NA	(25.3)	-
EBITDA margin (%)	22.5	24.5	29.0	NA	(650bps)	-
EPS (Rs)	12.1	15.7	18.8	NA	(35.4)	-

Source: BOBCAPS Research

### Fig 8 – Key assumptions

Parameter	FY23E	FY24E	FY25E
Generic APIs	26.1	28.7	31.6
Generic FDF	11.4	14.3	15.7
Synthesis (CDMO)	21.7	18.4	20.6
Biotech	1.3	1.4	1.6

Source: Company, BOBCAPS Research

## Key risks

Key upside risks to our estimates are:

- revival in ARV pricing and demand,
- accelerated approval of new products and higher utilisation of FDF capacities, and
- long-term supply contract wins.

Key downside risks to our estimates are:

- higher concentration and pricing pressure in ARVs,
- delay in formulation business ramp-up, and
- adverse regulatory outcome on manufacturing facilities.



## Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Ajanta Pharma	AJP IN	2.1	1,313	1,470	HOLD
Alembic Pharma	ALPM IN	1.3	556	615	HOLD
Alkem Labs	ALKEM IN	5.1	3,510	3,000	SELL
Aurobindo Pharma	ARBP IN	4.4	617	635	BUY
Cipla	CIPLA IN	9.0	908	1,250	BUY
Divi's Labs	DIVI IN	10.6	3,268	3,200	HOLD
Dr Reddy's Labs	DRRD IN	10.0	4,930	4,700	HOLD
Eris Lifesciences	ERIS IN	1.0	631	810	BUY
Glenmark Life Sciences	GLS IN	0.8	504	585	BUY
Laurus Labs	LAURUS IN	2.0	308	340	HOLD
Lupin	LPC IN	3.9	710	700	HOLD
Sun Pharma	SUNP IN	29.0	988	1,100	HOLD

Source: BOBCAPS Research, NSE | Price as of 28 Apr 2023

## Glossary

Glossary of Abbreviations						
API	Active Pharmaceutical Ingredient	СМО	Contract Manufacturing Organization Services			
ARV	Antiretroviral	FDF	Finished Dosage Form Division			
Bio	Biotechnology Division	GMP	Good Manufacturing Practice			
CDMO	CDMO Synthesis Division					



## Financials

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Total revenue	48,135	49,360	60,410	62,744	69,525
EBITDA	15,331	14,229	15,926	14,117	17,034
Depreciation	2,051	2,515	3,241	4,010	4,397
EBIT	13,280	11,714	12,686	10,108	12,637
Net interest inc./(exp.)	(682)	(1,024)	(1,652)	(1,545)	(1,545)
Other inc./(exp.)	237	153	60	125	139
Exceptional items	0	0	0	0	0
EBT	12,835	10,843	11,094	8,688	11,231
Income taxes	3,173	2,514	3,123	2,172	2,808
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	2	45	65	0	0
Reported net profit	9,660	8,284	7,906	6,516	8,423
Adjustments	0	0	0	0	0
Adjusted net profit	9,660	8,284	7,906	6,516	8,423

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Accounts payables	11,787	8,764	7,107	11,173	13,334
Other current liabilities	3,158	5,661	5,921	4,392	4,867
Provisions	757	892	1,016	1,055	1,169
Debt funds	15,799	20,774	22,074	22,074	22,074
Other liabilities	0	0	0	0	0
Equity capital	1,073	1,075	1,075	1,075	1,075
Reserves & surplus	24,934	32,516	39,409	44,936	52,352
Shareholders' fund	26,007	33,591	40,484	46,011	53,427
Total liab. and equities	57,507	69,680	76,601	84,706	94,870
Cash and cash eq.	485	759	482	1,618	2,964
Accounts receivables	13,061	13,542	15,804	16,331	18,096
Inventories	15,754	17,603	16,848	18,909	20,953
Other current assets	2,845	2,811	3,374	3,765	4,172
Investments	34	308	499	499	499
Net fixed assets	19,150	23,953	31,494	35,484	40,088
CWIP	3,622	8,132	5,508	5,508	5,508
Intangible assets	2,556	2,571	2,592	2,592	2,592
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	57,507	69,680	76,601	84,706	94,870

Cash Flows

Y/E 31 Mar (Rs mn)	FY21A	FY22A	FY23P	FY24E	FY25E
Cash flow from operations	6,914	8,118	7,798	10,125	11,353
Capital expenditures	(6,277)	(6,416)	(10,000)	(8,000)	(9,000)
Change in investments	0	(274)	(191)	0	0
Other investing cash flows	0	0	0	0	0
Cash flow from investing	(6,277)	(6,690)	(10,191)	(8,000)	(9,000)
Equities issued/Others	4	2	0	0	0
Debt raised/repaid	4,343	4,975	1,301	0	0
Interest expenses	0	0	5	0	0
Dividends paid	(1,006)	(1,008)	(1,008)	(1,008)	(1,008)
Other financing cash flows	(3,509)	(5,122)	1,818	19	0
Cash flow from financing	(169)	(1,153)	2,115	(989)	(1,008)
Chg in cash & cash eq.	468	275	(277)	1,136	1,345
Closing cash & cash eq.	485	759	482	1,618	2,964

Y/E 31 Mar (Rs)	FY21A	FY22A	FY23P	FY24E	FY25E
Reported EPS	18.0	15.4	14.7	12.1	15.7
Adjusted EPS	18.0	15.4	14.7	12.1	15.7
Dividend per share	1.5	1.5	1.5	1.5	1.5
Book value per share	48.4	62.5	75.2	85.5	99.3
Valuations Ratios					
Y/E 31 Mar (x)	FY21A	FY22A	FY23P	FY24E	FY25E
EV/Sales	3.7	3.6	3.0	3.0	2.7
EV/EBITDA	11.5	12.6	11.5	13.2	10.9
Adjusted P/E	17.1	19.9	20.9	25.3	19.6
P/BV	6.4	4.9	4.1	3.6	3.1
DuPont Analysis					
Y/E 31 Mar (%)	FY21A	FY22A	FY23P	FY24E	FY25E
Tax burden (Net profit/PBT)	75.3	76.4	71.3	75.0	75.0
Interest burden (PBT/EBIT)	96.6	92.6	87.5	86.0	88.9
EBIT margin (EBIT/Revenue)	27.6	23.7	21.0	16.1	18.2
Asset turnover (Rev./Avg TA)	33.9	25.7	25.8	24.0	24.2
Leverage (Avg TA/Avg Equity)	1.6	1.6	1.6	1.5	1.4
Adjusted ROAE	44.2	27.8	21.4	15.1	17.0
Ratio Analysis					
Y/E 31 Mar	FY21A	FY22A	FY23P	FY24E	FY25E
YoY growth (%)			-		
Revenue	70.0	2.5	22.4	3.9	10.8
EBITDA	171.0	(7.2)	11.9	(11.4)	20.7
Adjusted EPS	276.6	(14.3)	(4.6)	(17.6)	29.3
Profitability & Return ratios (%)		. ,	. ,		
EBITDA margin	31.9	28.8	26.4	22.5	24.5
EBIT margin	27.6	23.7	21.0	16.1	18.2
Adjusted profit margin	20.1	16.8	13.1	10.4	12.1
Adjusted ROAE	44.2	27.8	21.4	15.1	17.0
			21.8	15.7	17.8
ROCE	38.1	24.7	21.0	13.7	11.0
	38.1	24.7	21.0	13.7	17.0
ROCE	38.1 99	24.7	95	95	
ROCE Working capital days (days)					95
ROCE Working capital days (days) Receivables	99	100	95	95	9: 11(
ROCE Working capital days (days) Receivables Inventory	99 119	100 130	95 102	95 110	9: 11(
ROCE Working capital days (days) Receivables Inventory Payables	99 119	100 130	95 102	95 110	9

 Adjusted debt/equity
 0.6
 0.6

 Source: Company, BOBCAPS Research | Note: TA = Total Assets
 Total Assets

Current ratio

Net interest coverage ratio

2.0

19.5

2.3

11.4

2.6

7.7

0.5

2.4

6.5

0.4

2.4

8.2

0.4



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Ratings and Target Price (3-year history): LAURUS LABS (LAURUS IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

## LAURUS LABS



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquires, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to here in and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "**MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.